MapLight Therapeutics, Inc.

Our discovery platform holds the potential to fill a void by identifying neural circuits causally linked to disease and targeting them for therapeutic modulation. Utilizing this approach, we are advancing a robust pipeline of product candidates for some of the most challenging central nervous system conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. https://lnkd.in/gudWcFta

It's Throwback Thursday – and we're throwing it back to June with a snapshot of our recent offsite! Our team had a fantastic time connecting and collaborating. At MapLight Therapeutics, Inc., we value a strong and supportive culture that fosters innovation and teamwork. www.maplightrx.com

MapLight Therapeutics, Inc. is excited for our upcoming poster presentation at the Alzheimer's Association® International Conference (AAIC) in Philadelphia! Join us on Monday, July 29th, from 3:30 to 4:15 PM (poster 43) to learn more about ML-007's effects in preclinical models of psychosis and cognitive impairment. Looking forward to seeing you there! #AAIC24 #AlzheimersResearch #CognitiveImpairment #PosterPresentation

On World Brain Day, we emphasize the importance of brain health and the ongoing fight to support those living with CNS disorders. At MapLight Therapeutics, Inc., we are dedicated to advancing research and developing potential new treatments to support better brain health. Discover our progress by viewing our pipeline: https://lnkd.in/gWZG5wsj

Join our team! MapLight Therapeutics, Inc. is hiring for several key roles across various departments. Explore career opportunities with us and join a company dedicated to advancing treatments for neurological disorders. Apply today. https://lnkd.in/dgHz9Mrx

We are proud to partner with organizations like the Autism Science Foundation. Together, we are working to advance research with the aim of improving care and treatment outcomes for those with Autism Spectrum Disorder. Learn more by visiting our website. https://lnkd.in/gxwYtiwy

Are you familiar with our IRIS Clinical Trial? It's an important step in our work with Autism Spectrum Disorder (ASD). At MapLight Therapeutics, we are committed to advancing research and developing innovative treatments for ASD. Learn more about the IRIS Trial and our dedication to making a difference with potential new treatments for this community. https://lnkd.in/e9YaUN6H

This month is off to a strong start with the National Plan to End Parkinson’s Act signed into law on July 2, 2024. With this law now in effect, the U.S. Department of Health and Human Services (HHS) will establish the National Parkinson’s Project, a first-ever federal initiative to prevent and cure Parkinson’s disease, treat its symptoms and slow or stop its progression. Further, HHS will establish a federal advisory council that will provide recommendations and guidance for progressing against Parkinson’s disease and atypical parkinsonisms. This is a huge win for the Parkinson’s community.   Learn more via our partners at The Michael J. Fox Foundation for Parkinson's Research. https://lnkd.in/ePmyyBHh   #ParkinsonsDisease #Parkinsons #NationalPlantoEndParkinsons #NewLaw

Which of our therapeutic research areas do you have a personal connection to? Participate in our poll and let us know. Your feedback helps us understand and engage with our community better. Thank you for your input and engagement! If you want to share a story that explains your personal connection, please feel free to do so in the comments. ⬇️ Participation is voluntary and not required to participate in the poll.

Happy 4th of July from all of us at MapLight Therapeutics, Inc.! As we celebrate Independence Day, we honor the courage and dedication of all those working towards a brighter future for our country and people with CNS conditions. Wishing everyone a safe and joyful holiday! 🇺🇸